Vivid E80, Vivid E90, Vivid E95
GE Medical Systems Ultrasound and • Radiology • 07/22/2022
Device Purpose
The Vivid E80/E90/E95 systems are advanced, general-purpose diagnostic ultrasound platforms, specialized for cardiac imaging, that utilize a comprehensive suite of imaging modes, transducers, and digital processing capabilities for detailed anatomical and physiological assessment. These systems incorporate innovative software enhancements, including AI-driven analysis tools for automated measurements like ejection fraction and strain, CT fusion for procedural guidance, and advanced image optimization techniques, to improve diagnostic accuracy and workflow efficiency across a broad spectrum of clinical applications.
Summary
The Vivid E80, Vivid E90, and Vivid E95 are sophisticated, general-purpose diagnostic ultrasound systems primarily designed for comprehensive cardiac imaging, but also supporting a wide array of other clinical applications including obstetrics, abdominal, vascular, and musculoskeletal imaging. Operated by qualified physicians, these systems facilitate ultrasound imaging, measurement, display, and analysis of the human body and fluids. They feature a mobile console with advanced display and control interfaces, support a diverse range of electronic array transducers including those for real-time 3D/4D and transesophageal imaging, and are equipped for digital acquisition, processing, analysis, and network integration. Employing established ultrasound principles, these systems offer numerous imaging modes such as B-mode, M-mode, various Doppler modalities (PW, CW, Color), 3D/4D imaging, harmonic imaging, and coded pulse. Recent technological advancements include the integration of AI-driven tools like "Easy Auto EF" and "Easy AFI LV," which provide automated cardiac function measurements with high accuracy (dice scores exceeding 91-92% in testing across diverse datasets). Other significant software enhancements comprise "cSoundTM Adapt" for improved contrast, "CT Fusion Live" for real-time overlay of CT data, "Strain Elastography" for tissue stiffness assessment, and various workflow optimization tools, all aimed at enhancing diagnostic capabilities and clinical efficiency.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the 'Easy Auto EF' AI algorithm's performance (dice score >92%) compare to experienced cardiologists' manual ejection fraction calculations in terms of inter-observer variability and time efficiency in a real-world clinical setting?; What specific improvements in image quality or diagnostic confidence are provided by the 'cSoundTM Adapt' feature compared to previous adaptive contrast enhancement technologies in challenging patient populations (e.g., obese patients, patients with lung disease)?; For the 'CT Fusion Live' feature, what is the registration accuracy between the live ultrasound and the pre-acquired CT data, and how does this impact its utility in guiding complex interventional procedures?; With the addition of 'Strain Elastography,' what are the primary clinical applications anticipated for the Vivid E80/E90/E95, and how does its performance compare to other established elastography methods for these applications?; Given the wide range of clinical applications, from cardiac to fetal to musculoskeletal, are there specific transducer or software optimizations prioritized for cardiac imaging versus other applications, and how are potential trade-offs managed?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly